<SEC-DOCUMENT>0001193125-14-190998.txt : 20140509
<SEC-HEADER>0001193125-14-190998.hdr.sgml : 20140509
<ACCEPTANCE-DATETIME>20140509070634
ACCESSION NUMBER:		0001193125-14-190998
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140509
DATE AS OF CHANGE:		20140509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		14826975

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d721803d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;9</B>, <B>2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2014, Amarin Corporation plc issued a
press release announcing its financial results for the three months ended March&nbsp;31, 2014 (the &#147;Press Release&#148;). A copy of the Press Release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information set forth under Item&nbsp;2.02 and in Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;9, 2014</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;9, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;9, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d721803dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g721803ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Reports First Quarter 2014 Financial Results </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Provides Update on Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Conference Call Set for 8:00 a.m. EST Today - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, May&nbsp;9, 2014 &#151; Amarin Corporation plc&nbsp;(Nasdaq: AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health,&nbsp;today announced financial results for the quarter ended March&nbsp;31, 2014, and provided an update on company operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key Amarin achievements since December&nbsp;31, 2013 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recognized $11.0 million in product revenue from Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) sales in Q1 2014 compared to $2.3 million in Q1 2013 </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased productivity company-wide by advancing key initiatives, with lower cost and staffing levels than previous quarters, while maintaining Vascepa prescription levels in Q1 2014 that are consistent with Q4 2013
levels and positioning Amarin for accelerated 2014 revenue growth </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entered into a co-promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa Pharmaceuticals America) for the promotion of Vascepa in the United States which this month is expected to begin increasing
Amarin&#146;s sales detail frequency through a combination of primary and secondary details and over time is expected to more than double Amarin&#146;s current detail frequency </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reduced net cash outflow from operations to $27.5 million in Q1 2014 from $59.6 million in Q1 2013 (54% reduction) and $33.1 million in Q4 2013 (17% reduction), keeping the company on track to achieve the previously
reported targeted 2014 net cash outflows of less than $80 million </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Continued to improve formulary access such that Vascepa is now covered on formulary for more than 200&nbsp;million lives overall of which over 100&nbsp;million are covered on Tier 2 </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Surpassed 6,800 patients enrolled in the REDUCE-IT cardiovascular outcomes trial representing 85% of the total number of patients for which the trial was designed </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Continuation of the appeal process following the decision of the Division of Metabolism and Endocrinology Products (DMEP) within the U.S. Food and Drug Administration (FDA) to rescind the Special Protocol Assessment
(SPA) agreement for the ANCHOR study </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Q1 was an important transitional period for Amarin with a smaller team of people making broad
progress,&#148; said John F. Thero, President and Chief Executive Officer of Amarin. &#147;Our revenue per sales representative continued to increase as did overall prescriptions from our top targets. We also continued to reduce expenses
significantly. We look forward to our co-promotion efforts with Kowa Pharmaceuticals America beginning this month and to working with our new partner to expand detailing of Vascepa. We expect that our increased focus on key target accounts and our
broader detailing with Kowa Pharmaceuticals America will result in meaningful revenue growth from Vascepa.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operational update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commercialization and regulatory update </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin is
now available on formulary to over 200&nbsp;million lives in the United States, including over 100&nbsp;million with Tier 2 coverage. As the company works to continue to increase the productivity of our sales representatives and work with our new
co-promotion partner, Kowa Pharmaceuticals America, the company believes Vascepa sales will continue to grow with current Vascepa labeling. In late 2013, Amarin shifted its main focus to the approximately 7,000 targeted physicians who are
responsible for a significant portion of the prescriptions generated for the leading prescription omega-3 therapy indicated for the treatment of severe hypertriglyceridemia. During Q1 2014, prescriptions from targeted physicians increased while
prescriptions declined from physicians who were no longer prioritized for details after the company&#146;s reduction in sales force size. Normalized prescriptions (estimated) for the quarter ended March&nbsp;31, 2014, based on data from Symphony
Health Solutions and IMS Health, totaled approximately 93,000 and 78,000, respectively. Co-promotion with Kowa Pharmaceuticals America begins this month and, over time, is expected to expand the target physician prescriber base and more than double
current sales detail frequency, including resumption of details to physicians not currently targeted by Amarin&#146;s sales representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company
also continues to pursue FDA approval of Vascepa for the ANCHOR indication, a second indication as an adjunct to diet and exercise for adult patients with mixed dyslipidemia who despite optimized statin therapy have TG levels between 200 and 499
mg/dL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>REDUCE-IT and other Vascepa-related clinical development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enrollment for the REDUCE-IT outcomes trial of Vascepa continues at over 450 sites spanning 11 countries. Earlier this year enrollment for the REDUCE-IT trial
surpassed 6,800 patients representing enrollment of 85% of the total number of patients for which the study was designed. Results of the REDUCE-IT study will not be available until a specified number of cardiovascular events have been observed.
Based on current expectations, unless feedback from pending discussion with the FDA regarding the ANCHOR sNDA results in modification or termination of the REDUCE-IT study, completion of this blinded study is anticipated in or about 2017. Amarin
estimates that over $100 million is required to complete this study. While Amarin remains scientifically committed to continuing the REDUCE-IT study, Amarin anticipates that the trial may be difficult to complete in its current form without the
expected revenues from the previously anticipated ANCHOR indication, as communicated to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net product revenues for the three months ended March&nbsp;31, 2014 and 2013 were $11.0 million and $2.3 million, respectively. Vascepa became commercially
available in the United States by prescription in January 2013. In accordance with U.S. generally accepted accounting principles (GAAP), as previously described, until the company had the ability to reliably estimate returns of Vascepa from its
distributors, revenue was recognized based on the resale of Vascepa for the purposes of filling patient prescriptions, and not based on sales to such distributors. During the three months ended </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
March&nbsp;31, 2014, the company concluded that it had developed sufficient history such that it can reliably estimate returns and, as a result, began to recognize revenue based on sales to
distributors. Consequently, the company recognized revenues of approximately $11.0 million based on sales to distributors during the three months ended March&nbsp;31, 2014, compared to revenues of approximately $10.0 million that the company would
have recognized consistent with past quarters based on the resale of Vascepa for the purposes of filling patient prescriptions during the period. Cash collections from the sale of Vascepa in the quarter ended March&nbsp;31, 2014 were approximately
$11.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of goods sold for the three months ended March&nbsp;31, 2014 and 2013 was $4.2 million and $1.3 million, respectively. Gross margin
improved to 61% in Q1 2014 from 45% in Q1 2013, which was primarily driven by lower unit cost active pharmaceutical ingredient, or API, purchases. The majority of Vascepa capsules included in cost of goods sold for both periods included API sourced
from a single API supplier. Amarin&#146;s purchases of API from this supplier are at a higher cost per kilogram than Amarin&#146;s other API suppliers due to more favorable economic terms under such supply agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under GAAP, Amarin reported a net loss of $26.0 million in the first quarter of 2014, or basic and diluted loss per share of $0.15. This net loss included
$2.0 million in non-cash share-based compensation expense, $0.1 million in non-cash warrant compensation income and a $4.4 million gain on the change in fair value of derivatives. The company reported a net loss of $62.2 million in the first quarter
of 2013, or basic and diluted loss per share of $0.41 and $0.43, respectively. The net loss in Q1 2013 included $4.9 million in non-cash share-based compensation expense, $0.5 million in non-cash warrant compensation income, and a $3.6 million gain
on the change in the fair value of derivatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Excluding non-cash gains or losses for share-based compensation, warrant compensation and the change in
fair value of derivatives, non-GAAP adjusted net loss was $28.5 million for the first quarter of 2014, or non-GAAP adjusted basic and diluted loss per share of $0.16, as compared to non-GAAP adjusted net loss of $61.4 million, or non-GAAP adjusted
basic and diluted loss per share of $0.41 for the same period in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin reported cash and cash equivalents of $164.3 million at March&nbsp;31,
2014, representing a net decrease of $27.2 million from reported cash and cash equivalents of $191.5 million as of December&nbsp;31, 2013. Net cash outflows in the three months ended March&nbsp;31, 2014 included approximately $13.9 million in sales
and marketing related expenses and approximately $7.5 million of costs incurred through the company&#146;s clinical research organization and for clinical trial materials in support of the REDUCE-IT cardiovascular outcomes study. Net cash outflows
in Q1 2014 also included approximately $2.6 million for Vascepa inventory purchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In aggregate, net cash outflow from operations was $27.5 million in
Q1 2014, as compared to $33.1 million in Q4 2013 and $59.6 million in Q1 2013. The decrease in cash outflows from operations from Q4 2013 to Q1 2014 of $5.6 million, or 17%, was achieved as a result of our focus on cash preservation and targeting
spend efficiently in order to maximize Vascepa revenues and minimize cash burn. It is anticipated that the company will experience continued reductions in quarterly net cash outflows from operations. The company continues to estimate that during
2014, net cash outflows will be less than $80 million. Based on the company&#146;s current cash position and anticipated burn rate moving forward post the reduction in infrastructure expenses executed late last year, the company anticipates being
able to reach a position that is cash flow positive, under the majority of scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&#146;s liabilities as of March&nbsp;31, 2014, excluding the
fair value of the non-cash warrant derivative liability, totaled approximately $271.9 million, which includes $150.0 million for the carrying value of exchangeable debt and $95.8 million for the carrying value of the hybrid debt-like financing that
we entered into in December 2012. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, Amarin had approximately 172.9&nbsp;million American Depository Shares (ADSs) and
ordinary shares outstanding as well as approximately 9.8&nbsp;million and 11.6&nbsp;million equivalent shares underlying warrants and stock options, respectively, at average exercise prices of $1.41 and $5.60, respectively, and 2.2&nbsp;million
equivalent shares underlying restricted or deferred stock units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin&#146;s operational priorities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&#146;s current operational priorities are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increasing revenues from sales of Vascepa </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Continuing discussions with the FDA and vigorously pursuing the approval of Vascepa for the ANCHOR indication </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Continued focus on cash preservation and expense management </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference call and webcast information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&nbsp;will host<B> a conference call at&nbsp;8:00 a.m. ET&nbsp;</B>(1:00 p.m. UTC/GMT) today,&nbsp;May 9, 2014. The conference call can be heard
live via the investor relations section of the company&#146;s website at <U>www.amarincorp.com</U>, or via telephone by dialing 877-407-8033 within the United States or 201-689-8033 from outside the United States. A replay of the call will be made
available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (inside the United States) or 201-612-7415 (outside the United States). A replay of the call will also be available through the
company&#146;s website shortly after the call. For both dial-in numbers please use conference ID 13580493. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of non-GAAP adjusted financial
information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Included in this press release and the conference call referenced above are non-GAAP adjusted financial information as defined by U.S.
Securities and Exchange Commission Regulation G. The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial
measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-GAAP
adjusted net loss was derived by taking GAAP net loss and adjusting it for non-cash gains or losses for share-based compensation, warrant compensation, and change in value of derivatives. Management believes that these non-GAAP adjusted measures
provide investors with a better understanding of the company&#146;s historical results from its core business operations. While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors
regarding the underlying performance of the company&#146;s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.
Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company&#146;s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures
may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl),
Amarin&#146;s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vascepa&reg;&nbsp;(icosapent ethyl) capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly
pure-EPA&nbsp;omega-3 prescription product in a 1 gram capsule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or
shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT&nbsp;<U>WWW.VASCEPA.COM</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the FDA as an adjunct to diet to reduce triglyceride levels in adult patients with severe (<U>&gt;</U>500 mg/dL)
hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed as marketing the use of Vascepa in any indication
that has not been approved by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the future commercialization of Vascepa, including the planned expansion of
promotional efforts resulting from the co-promotion agreement with Kowa Pharmaceuticals America, the anticipated increase in prescriptions, expectations for revenue growth, product awareness, receptivity of clinicians to and patient experience with
Vascepa; expectations regarding managed care coverage migration from Tier 3 to Tier 2 and continued growth in Tier 2 coverage; the pricing terms of commercial supply for Vascepa; expectations regarding cash burn, gross margins and cost of goods
sold; expectations concerning the likelihood of future fundraising; the likelihood of becoming cash flow positive; the FDA review of Amarin&#146;s sNDA for the ANCHOR indication and related SPA rescission appeal and Amarin efforts related to such
interactions; the efficacy, safety and therapeutic benefits of Vascepa; the ability of Amarin to continue the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
REDUCE-IT study in light of company resources and other factors; Amarin&#146;s ability to obtain sufficient patent protection for its product and product candidates; and continued enrollment and
following of patients in Amarin&#146;s REDUCE-IT cardiovascular outcomes study. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with
the U.S. Securities and Exchange Commission, Amarin&#146;s ability to effectively commercialize Vascepa will depend in part on efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales
activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, and to maintain patent protection for
Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory
approvals; the risk associated with the FDA&#146;s October 2013 rescission of the ANCHOR SPA agreement; the risk that FDA will follow the negative recommendation of the advisory committee; the risk that the recent reductions in expenses will not be
sufficient or will hurt sales; the risk that historical REDUCE-IT clinical trial enrollment and randomization rates may not be predictive of future results and related cost may increase beyond expectations; and the risk that patents may not be
upheld in patent litigation and applications may not result in issued patents. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S.
Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important information regarding prescriptions data and product revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical prescription data provided in this press release is based on data published by third parties.&nbsp;Although Amarin believes these data are
prepared on a period to period basis in a manner that is generally consistent and that such results are indicative of current prescription trends, these data are based on estimates and should not be relied upon as definitive. These data may
overstate or understate actual prescriptions. Based on other data available to Amarin and the history of such third-party prescription estimates in the early stages of launch of other new pharmaceutical products, Amarin believes that the trends
provided by this information can be useful to gauge current prescription levels. Amarin commenced its commercial launch of Vascepa on January&nbsp;28, 2013. Accordingly, there is a limited amount of information available at this time to determine
the actual number of total prescriptions for Vascepa. Amarin believes that investors should view these data with caution, as data for this single and limited period may not be representative of a trend consistent with the results presented or
otherwise predictive of future results, especially in light of the October 2013 negative advisory committee vote, the October 2013 reduction in our sales force by approximately 50% and the March 2014 co-promotion Agreement with Kowa Pharmaceuticals
America. Seasonal fluctuations in pharmaceutical sales, for example, may also affect future prescription trends of Vascepa as could changes in prescriber sentiment and other factors. Amarin believes investors should consider its results during this
quarter together with its results over several future quarters, or longer, before making an assessment about potential future performance. The commercial launch of a new pharmaceutical product is a complex undertaking, and Amarin&#146;s ability to
effectively and profitably launch Vascepa will depend in part on its ability to generate market demand for Vascepa together with its new partner, Kowa Pharmaceuticals America, through education, marketing and sales activities, its ability to achieve
market acceptance of Vascepa, its ability to generate product revenue and its ability to receive adequate levels of reimbursement from third-party payers. See &#147;Risk Factors&#151;Risks Related to the Commercialization and Development of
Vascepa&#148; included in Part II, Item&nbsp;1A. Risk Factors in Amarin&#146;s most recent Annual Report on Form 10-Q. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of other information about Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations
website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference calls and webcasts. The
information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including
our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin contact information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Farrell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908)&nbsp;719-1315 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEET DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(U.S. GAAP) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, long-term</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant derivative liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-Term Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long- term debt</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long- term debt redemption feature</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">277,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Deficit:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(939,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(913,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(U.S. GAAP) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,<BR>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative (1)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (1)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on change in fair value of derivative liabilities (2)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Provision for) benefit from income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Excluding non-cash stock and warrant based compensation, research and development expenses were $11,069 and $21,024 for the three months ended March&nbsp;31, 2014 and 2013, respectively, and selling, general and
administrative expenses were $19,338 and $35,658, respectively, for the same periods. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Non-cash gains and losses result from changes in the fair value of a warrant derivative liability, a long-term debt redemption feature and forward exchange contracts. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECONCILIATION OF NON-GAAP LIABILITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-Term Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long- term debt</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long- term debt redemption feature</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities - GAAP</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">277,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant derivative liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities - non GAAP</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">271,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECONCILIATION OF NON-GAAP NET LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,<BR>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for EPS<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> - GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant compensation income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on change in fair value of derivatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss for EPS<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> - non GAAP</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted - non GAAP</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g721803ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g721803ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P$Y`P$1``(1`0,1`?_$`-@```$$`@,!`0``````
M```````("0H+`P<!`@8$!0$``@(#`0$```````````````<%!@$$"`,"$```
M!@$#`@(&`PH("0D)```!`@,$!08'`!$($@DA$S&1(E(4"D%A%H&AL3)B(S,5
MMG=Q0G*R)!<8.5'1@G.C9-4W>/#!E;5VA[<X&>$T)29'*$A8&A$``0($`P,'
M!P<*!@$%`0```0(#`!$$!2$Q!D%1$F%Q@9&A(A/PL<'1,A0'X6)RLB-S%?%"
M4I(S)#0U%C:"PM)3="5#HF.#1%15_]H`#`,!``(1`Q$`/P"?J<_0&XAOX[?A
M_P`6B",?GA[H^L-$$'GA[H^L-$$'GA[H^L-$$'GA[H^O_P!FL%0'M83\L=T!
MPAI#N4=YSBEVRYG%%-RP\=7')&3;;6V;S']1D60SU!QE(RR#&R9=N*:B;D8Z
M`@&9SK-&ABE=3"J1DV^Q2J*IVG3VDKKJ)MUZE3PL-(4>(Y*(_-2<)D]D0MTO
ME':UH;=(4ZM0!$\4@[3GB=@V[P,8==AYZ*L,1%6""?-)>#G8UA,PLLP<$<L)
M2)E&J3Z.D63A/J379O6:Y%4SE$2F(8!#PU65I4VXIMP$*3G/9+`](.R)A"TK
M0'$^PK([YY=<?I>>'NCZPU\Q]0>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'N
MCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'N
MCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'N
MCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'N
MCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'NCZPT00>>'N
MCZPT00>>'NCZPT00>>'NCZPT01W(H!QV`!#PW_!_CT01DT01A7_$#^4'X!T0
M1\NB"#1!!H@AN;NR<D.07$?@-GWD-QGJ]0L^3,:UYO+]5T=&)%U:LKO$F%AO
M#:)Z2HVB5J39T5VA&*JH).>@>HQ^GR59_2]OHKK>V+?7*4&'5@'AS*M@.X':
M<XBKU4U-%;W*JE`+J4[<@-_.#%2)EC+.2<ZY$MN6<Q76?R/DF]RKB:MMQM+]
M61F)J0<C^.LJI["#1NELDW;I%3;MD"E32(0A0*'5M);Z.A8324J`BE0`$I&0
MEMY^6$14U3]6\JH?45.DSF8L2_E<^X@/)KB&]XEY"G!>YCXC-H^)@#OG(JR5
MJP+*+JI4F2(*GYQRI1GI5(-P.XBFW(Q$?%37/OQ*T_\`A5V%R8$J*HQYE[?U
ML^><-O1]T%=0^[.G[5G9O_)YB(E$Z6L7&#1!!H@@T00:((-$$&B"#1!!H@@T
M00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:
M((-$$&B",R'XX_R1_"&B"/JT01A7_$#^4'X!T01\NB"#1!!H@YHBK?,5YSN^
M>;KQ0[.''R34/E'E_D*LV',9H]0PC7L21<P)HAK-"DH`)1SU['/)IV13;^B0
M1=_95#=E:"HF:)FJU96I_=J5)"-LW"//L!V13=45"ZE35FIR?$=4"J6P9#U\
MPB%)W2N`EG[;O,?(O'"8<R<Y3VI&-NQ%=9)!-!:[XRL)#GA)=<6Y"L_UK'/$
M'$?($2]A-XU/L`%,73KTMJ!K4=K16H2$O\1"T`^R1LZ<P=T+:]VERT5II53*
M<PK>/R>F/R>V-S?LG;UYIX=Y*PYW3FMP,S]F<K0#4Y@^U&([2HA'W:)\K8Q%
MG;1F4D@SZ@'I?,D3?1K&J+*U?K._0KDET'B03L(&$N3""QW$VRX-U0GX<\1O
MY.KME%OM3;A6<A5&KWVES#.PU"ZUZ&M=6G8]4%F,Q7Y^/0E(F2:J!MU(O&+D
MAP]`AOL/CX:Y/=:<IWET[Z2EU!D1N.4/=IQ#S:7FR"VI,^>>75MCTFO./2/B
MDI%C#QTA+RCI)E&13%W)2+U<W2@S8,&ZCIX[6,`")4F[9(QS#L.P!H"5K4E#
M8FM2@`.>,*(2DJ40$@3)/)#7I.][VE5`W)SVP"?ZR6&0-]7T10^&^K&G2&IE
M94;IGE*1$N><0Z]0V5L]^H0.@^J,G_K<=ICZ>>6`_K_^8)'_`&3K[_HW5`('
MN3W$=AD)]L?/]26+94HZCZH<)Q1EG&N=,=53+F'KI`Y$QI>8T9>I72LO`?0<
M]'`Y79F=,'(%(8Y4W;91(X&*4Q%"&*8`$!#5?JJ>HH:A5+5H4V^@R(.PQ+,O
M-5#8>84%-G(B-A:\9$9QZP:((13R%[CO!7BA>&N-.1O*'%.(;^\@6=F0J5NF
MUFTT:!D%W39A**-&K1T9!L\69J@GYG28W0(@`AL.I>WZ?O=T9-1;Z=UUGBE,
M`2$LQGC$=5W:VT2_"JGDMN9R,\HT2/>X[3'I_MYX#V_[02/H_P"BM;QT=J<"
M?N;TN8>N-8:BLF1J6Y]/JA4?&GG%Q&YD&N!.+F?L?9N/0`AQN9:-(KR`UP)_
MX_\`4PR7GM6WE?K(8MQY6W5OY)O\&HNX6BZ6DI%S94R%C"9&)YA&_2U]'6S%
M,L+(W3RZ1"J=1T;<8G#ANT07=NUT&K1JBJY=.G*I$&S9L@F95=PX75,5-%!%
M(@F.<P@4I0$1$`T`$F0F23+#'.,$\(XC[(SQE(;3T1HOCOR?P%RQI<KD3CKE
M"M97ID'<K)0):=K"ZZK5C;:D]%A-Q2Q'2#=?=)3I416`HH.FZB:R)SI'*8=V
MOMU=:W_=Z]M3;A`4D':DY1X4U53U:"NG6%I!V=8[(WSK2C8@#_E_C^YK.<X,
M(1%E#N4\`\)9(LN'\O\`+K!>-,H4XT<6ST>[7F-KU@AQEHUI,1H.F<B=#P>Q
MCY%=,2"8!34`=2U/I^]UM.FJI*=Q=,K)21,&6!ZC$=47:W4KA:J'DH=&8,:[
MD>\)VMXM+S7G/'C5T[";^C9(B7YND!`!_-L#.5-]Q]&VMI&D]2.8)HZC]7UQ
MX&_V48FI1*-=/N^QVAHU3RG7/+"@J>(;-%[0^+N'Y;.N+DV'?P'?8?HU[?T9
MJDR3[FX%\LA,=*HQ_4%H(FEX*&\!1\PCW5'[R':SR,^;QM3YU\>7+UT<B:"$
MQ=$ZJ*AU!`"$!2U-X9$#"([>)@V'7@]I/4S">-RC=X!M&/FG'VW?;0X>$5".
M/<<//*'#JU:ZM=89K8J99:_;J^^*"C&=J\S'3\,\(8`$#M9.*<NV2Y1`0'<I
MQU!.,NL+*'DJ2O<1(CKB20ZVZD+;4%(^:9Q^]].O(F7-'ID)F$$YN[H_;SXV
MY*F\.9WY;8AQ=E&MHQ3F=I%IF7;2=C$)N/0E8I1TW28+D(5_'.4UD]C#N0X#
MJ=HM-WZXM!ZBIG'&E>R1+'K,1K]WMU,LH?>0D@RVX<^$:J_];CM,^@.>>`]_
M^T$A_LG6W_1NJ)R-$]/F'KC7_J*R`=ZI;ZSZHZF[W?:63#<_/7`10_PFL$@`
M>L8K7RK1VJ$YT;H/++UQ])U!9E&2*ALGG/JCJ3O>]I0X[$Y[X`-]1;$_$0^Y
M^JAUDZ-U1G[D]S8>OT1DW^SC!3Z`>F77*.__`*W/:7__`'SP'_T_(_[)UG^C
M-4G_`.D]V'TQC^H;)_\`H;ZSZH67QTY6\;N7%4EKSQGS/1,TU2!FC5V<F*/+
MDDDH>:*V2>!'R;<Q$'C%=5JL51,5$RE5+N)!-L.T-<+9<+4Z&+BTIEPB?>VC
MDC>IJVDK4%VD6%M@R)&P^J%`ZTL\HVAEOC26>N2>`N+=-9Y"Y%Y<HV&:1(SK
M2L,;1?YQM`P[NP/V[MVSAT';D0*H_<M6"RA2!XB5(P_1K;HJ"MN3W@4+2W'0
MF9"1.-:HJJ>C;\:I<"4$X<6$(Z5[S/:I0-TJ<]..1A$H&`4+RW<D$IO0(*-T
M5$Q'ZM]]3`TAJ?#]R?(5EA(]4:"K_9@J7O+8D,<SVQMWCWW(N"7*?(SC$W'7
ME'BG,&2&M?DK0O4*7-+R,LG7H=S'-).7Z#,T43,F3F5;$.8#CL98NM2NT_>K
M8S[Q<*=;3/$!-4LSD,Y[(V*6ZVZN7X=(Z%KD3@#YY2A<NH>)",2P")0``$?:
M#T?P#]0ZP<ML$?/Y9_=-_P`ON:P.([>L>HQG#;Y=4`D$/`=@'_`)B@/J$0UF
M2^0]!]<?)*=X'ERQX#)^3:7A['-\RM?YMG"4C&U1L-WMDJLX0`K&`K$6ZEI-
M8H&5)UK?"M3`F0!ZE%!*4/$P!K8IJ9^KJ6Z5D3><4$@">:C@3G@(\7JAJG96
M\X>ZE,\QLV1%&[`5%N?/?FES-[TF;(IP`V^US.'>-,?)"=4E;K::;5":-$`M
MN"256IC6+A$U"^!EUW_TB8=,W6[K-CM%)I2B/LI"WI;5;092G,S(GLE%/TVA
M5QKW[T^3B2E(W98C&6`PZ3"I/F:^W8MRZX6CR#Q[`B_S=Q#3F+N@FR;`K)VG
M#3M)-;)E;`44C.72D`U9DG6B>^Q19KD*&ZPZCOAO?A:;Q[C5*E15/=)GDH8I
M/)/V<]TXV=76L5U`:AL$OLC9F4G/?EGOSBLY`P'`I@,!BF#<I@VV$IO$!#ZA
M`==*2!QA,D%)((D=L6'?RIW</#-/':R\%<BS8+9&XU-QGL4'?+A\98<&S3\Q
M1BVWF"!G"N.K&Z^'Z0W$C!ZV``Z4QUSW\3M/BAKQ=Z8'W=\_:88)<V="AVB&
MWHRZBJIOP]Y7VK0FGIS'1Z>2);FE9%YC$N@@Z06;.44G+9RDH@X;KID60<(+
M$,FL@NDH!DU454S"4Q3`(&*(@/AK()20H9B,$`B1`(,1,?F>N$G$ND]N23SM
MC[CKB;'>5J/F#&#"+NN.:-`4B6&$M4JZAYZ*F#UEC&HS$6]07*8".BJ>6NFF
M<@E$!W:'PXO-R=U"BBJ'W5T:FUS2I1,N$3!$\B#NBDZLME$W:E/,M(0\%IQ`
MEG,;(@&Y>PY><'6J,J&08C]52TU1L?9(A3D$RK.8I>3ZA$W>H3L<N8B97#60
MA)E,#"`>PNFHF/M$'3]HZUBM07F%<:$.*3LG-)ET0JJFG=IB$N`CB`4.8@$>
M7+$V[Y1[GD6<IN5NWK>YDGZSI2LAFG!";Q8`4<567>HH9-J3$5#;G_4D^Z;R
MR*)`W\M\Z/MTD'9)_%6P!E]N]LI^S<[KDMBIDI)Y\CT0R]"W4.M*MSZN\G%,
M]VWUX\L35_X-)T2EA#`$Y8YQXO)&0JEB3'MXRE?95O!TG'53G[K:Y=RH1-&.
M@*U&.9:4<&$YB`8Y&C4W07?<YQ`H>(AKV88=J:A%,P.)UQ02!RF/)]]%.RM]
MW!I"22>7=%1GW(LBYLY39C=\_P#+<>M$5KF/;\DS&$HMZJN=VRQ;BB>9T2"9
M-D%R_F(6*;D(R1.4P@NY;N%/IW-U9IFEI+72"RTI"G:9"?$4-JE"9!Y81E[>
MJ*JK-<^"$.%13S##L.'1'Q=IW%6/<X=R;A=B?*M8C[ICF[YQKT9;JE+%4/$V
M&*0:2<G^JI1),Z9G$<Y<L$P62Z@*LGN0VY3"&OK5]5446G:JII5%%0AHE*MQ
MRVX90:>9:J;NTR^D*:*A,'G$6W.,,%82PBU?,L,X?QAB9I*$:)RC?&U$K-*2
ME"1X*E8%DBUV-COCP9`NIY7F]?E]9NG;J'?E6IKZVN(56.N.J&7&HJES3G#Q
MIZ2FI9IIFT(W\(`\T;4UJQL<\0??FGNY-RNQ)D.&X&XXFX3&N%\DXGBKY=+/
M39]17)V0XR8DYB$?TNQG2!!Q1ZHFYB3@+=`15F$3")U?)ZD=.;X8Z;ME:W^-
M50*JMM9"4J'<!&T;%'GG"[UG>:NF<]P8(2V1WI9F8\T-8?+3]R,.&7,1/`.1
MIT(_C_RR?0U/D%'K@$HJEY@1-\'CNWB*AR(,FTR=<85\<=BB1RW4..R`:M/Q
M&TX+K:/?Z<?OM."0-I0/:3Z1S2B"T?>#15HIGE?8.F1GO.1ZSU$Q9I"`@(@(
M;"&N;QY>7EE#@&(GY3CC6=DMD9AO[GCP\XJ9KX^\D[-E7CMAN\VYQA'([\]V
MG<>UAS>4W]>HTLZ@7[:Y_JXMF:OH9=@@9LJFZ*='RB@40*&VIVRW6Y4M:PW3
MONH;\9`X0H\,BH3[N6,\8B;E043],XIYI"EA!Q(QP22,<\)13QH`'E)FV*)A
M(41$2@(B.P>.^WIUUT,0"H`JD-G)"$=)XU#&4S%@9\K3Q6XUYM[=V3K%F?`.
M&,LS)^3]ZA$)?(V,Z?<9=M$,:3CQ5"-0E)^)?OD6"3AXHH1(ARD(=0P@&X[Z
M07Q.NUQH]0):I*AYM`91@E:@,21E/=#2T90T=1;EKJ&FUKXP)E(/YHA6G<[^
M6\X8<C\.WBW<4L65[CGR2K<!+3],#'R2D1CS(,K&LUWJ5.MU**HI",PGCH@W
M;R#%)JNU7.4Q_-3`Q!B=-?$*[V^L0S<G%/6Y1`5Q$<:<<YRQ&^9YI1(WC2UO
MJ*=;U&GPJA,R)3QD,I3S.^("O$/GCR[X`9(0N7'/+5JQ[(P\F*%EH#UXZE,=
M6D&+HR4A!7*A/5S0<DD91$R1U`32>(#N9)5,X`;3UN]BLM^I"*MI*N(8+`[R
M01,$$2.$+"CNMPM;X\%:I@F8V=.^8WQ:,=IWN-U7N><1Z]R"C(!"E7N(FGU!
MS!0F[L[UG5LA0;=FY>##.EA^*<UF?CWZ#^/,L'G%07\I0142.8>:=4V![3=V
M7;W#QL%,T*EFD[^79#FLEV1=Z%-2!PK!D0-ASGT[HV%S=X?<5\\X1S[+Y?X]
MX@OED>X?O:A[E/4&M.;R@XA*=*+0KQC=!C@LK%[#J-4S-54G)3H>6`%$`\-:
M]ENERHZVG:IGW4-!Y`X>(\,B0#@21V1Z7.WT-12.NO--J<"%&?")S`)&.<4Z
M20[I)F$=Q%-,1$?3N)"B.X_3N(ZZ[;40$F>:9GE,(%>"R!*4SLY8GN?*K<).
M)V5>'N4^065L!XSRGE<^?K-0&5FR15HF[A"U.`J%+D6$7`QEC:R$7#BH^G'"
MBZR*)5UA,4#'$I"@"'^)]ZN=-=T4E,\XU3^"%$)44S))$R1B<H:.C;;05%`I
M]]IM;W'*:@#L!YH=-[R7;EX*O.W-S#R)'\4\'5+(..<(W3(=*O-#QY6J+:H*
MUU2-/*Q+]"8JT?%NET!71Z'#=85$'")S$.4=P$*UI*_7@Z@I&#4O*:<=2E04
MHJ!!.7>GUYQ,7ZU6_P#"JAY++:7$)FD@2,^B*V&S<6<U5/C?B[EK(5!=S@7+
M5IN%%K][CC"\CHN[TF1.PE:K9RI%ZH"4?)E^)C_.V3?(`?RC&.FH4O1:;O0.
MW-VTI6!7M2)2<)A6((A2N6^J11IK5)_=E3`4!/$;_++'?"@.VSW&\X]L[D/#
MYMQ&]5EJV_%M#9:Q4]>+-ZQE*E>>!W,5(IE$R;2>CRF,M%2($,JR=>\D=5,\
M?J73='J2WJIG0/>$CN*VI/(?(1L66]5%IJ@ZW^R)DH;".;RY(M9>&/,K!G/'
M`50Y$8`LR<[4+.AY$G%.131LE(M#9)(9FF6Z-*<RD9/PRZG2<H^PLF)%DC'2
M4(8>7KO:*ZR5RZ"M2?%3B#L4-A'/#MH*^GN5,*FG5]F<]Z3NC>&1,78RR]`%
MJF6,=T;)U7(^;RA*YD"J0=P@B2;,%`:R)(JP,9!B1\V*J<"*@3K*!S``[".M
M.GJ:FE7XE*XMIR4II)![(V'F6GT\+Z0M.XB?GB"#\R3VO>,^&^1W!VY<?:?!
MX1)S`RDYPWDBJT>(;Q=-:2R5BHS)I?H&N-02CHB459715-VW:D2;KBV2/T`<
M3F,Z_A]JJY/V^M36+<>-*UQH*B9@$';T;87&JK+1HK*=5.D(2X2"!E,$;.DQ
M--XL\&N*/#>JUNI<>L&8WQ\M6JTWK!KC$5*%2R!8&R230D@[LUV%F:RS;V;=
M-"N'9EW)RJK``[`!2@"@N%YNEU6MRN><6E2Y\)42G;*0RPRRB_TEOHJ%"44Z
M$AQ(`)EB<-^>,*[U&1NPV#W7H/&4UQ]J/]:>">8'(.#997@UV-+X5SML@<HL
M956N6ILG8)IQ3[E2)!Q2F;155%RFHZ41^*<-S"D)BE,6P:<54)K%FF>IV%^'
M[3H!21,8"8(GMY@8A[TEE5,D/-O.)X\FYS&!Q,MGIE$=Z0HW"?I*XDNUMW^U
M0+LD512^YU7,7J$1`H%2Y`',`"/U;:O2%W<3X;E:Q_@1_HBJK%N($Z6X=:O7
M'C7^-.`:QUWSCM<=_LFX`=42V?-BX@!`*7P%7-;AP<=@^D3#K834WD"0N%H/
M.E(\R1'D46Q1F:2X8<JO7#2'<F0XHR$5CKC3PYX<=RS$/*7+-NA3)UWE!;\F
M/9.ST)X,DP+%4_&$G?;(-P>V>>2!(%%D$T4BM%-C"8PB2VZ<%Q2IRXW.JH'*
M)M)EX24^U\Y1`X0(AKJ:)?!24+%2BI6<0LG$'=/?#N^$.,G"O%V.Z947G:&[
MVP34-"QC6S3\%,Y#K+.Q3X,VPV"Q#`T[/%?AH\)F4*HL*#9JD4A3`&VX;ZJ5
MPN5WJJA;WXI;?#*CPB23(;!,I).'+$[34E`VTE'N57QA(!DI0F1F9`P\YVX.
M.O%!]EB?OU'X0\_>-]II=1>LVDCS%N&5WU&MT/>VSVNSL+#5RU9CR!6;#(A%
MF/\`$)NF/4W15*<A@,/A3K_<KC[NAIZKI:COX!E*4J24Y&:4I,AGF8G[52T2
MG5K0R^VOAE)9)!&T8YQ`W[V';[=]N_G?DC&D)%N&N%<D+.<M8#?"10S0:%9W
M[A5W5".3$(51YC^P?$Q9R^)OADVZ@^"H:?.BK^+]9$/.*'OC7<<&V>_;B<Q"
MQU+;#:[BI*`/!4>)/-NRZ.CEA*/`;F!<^!_+C"W**E'<KJXYM*![7!(*J)DM
MN.YD!BKU5'`$,4%"2U><K>4`^!'1$CAXD#4GJ"SM7RTNVYV0)2>$\HQ'4<8T
MK/<%V^X-U(P2"`?3U[8N%<4Y.I6:\9T++V.)EO8:'DNHP5VJ4RU4342?P5BC
MD))@J;RS'!-PFDX`BJ8CU)*E,0VPE$-<DU5,]1U+E)4CA?;601NEEUYP^F*A
MJIIT5#1FAQ(4.:4>^UX1ZQ'F^:,;"OV?LQ*`<"_"9/PBZ$-A'K`+['H]`"'X
MH[K[[_5J^?#<@:J9)R\-SZL5C5PG9E?>-_6AA_O9<$!O?:2[97/RD0QEK+AC
MBKQWQ/FA5DWZEG>++11:\I2;"^%-,3F3IUV>G:&4,(]*$SX[$2#:\Z-OJ:35
ME?9WR?!>J%J1])),P/I"4^:*MJ&V>\6.FN30^T2R@*ZL#R[1U1&)X3\J+EPG
MY4X1Y048ZJDMBBZQ\U)Q9%#IIV*HO`4B[I5G708O6VL%7>NF^P[@4YRG])0V
M9=\M35YM+ML?P"TG'YP_TX=D4ZUUJ[?7HJ6B9`CI'+OZ8N+<391I>;L7X]S#
MCF70G:'D^G5^\U*60.0Q'L%98QO*,#'`AC@FX31<="J8CU)JD,4WB`ZY'K*5
MZCJ'*2H'"^A1"ARCRG#[IWVZEA%0T9M+2".:(\'S#F<KQDR.XU=I/C^_5#-G
M/K(,&PO:D>8YEJK@>#FDCS4A*`D.[:-F9)FHLL8^Q3,(AT4=P-J]:#HFJ85&
MIJ^7NM&D\/*LC`\^P'?%9U-5+<#5HIL7GE@GFG(=N)&X&&`_FF<+4KC9;.V]
MQZQJQ)&X_P`/<3YNEUAF0A"&,VA[>T8+R+GI#VY"87;"Y<GW]M=0YO28=7_X
M85;M>FXU[\_&<J0H](RZ!AS14=;4R:,TM*CV&V9=N)Z3#279'_O:N`_[_P"&
M_P"HI_5JUU_:U7]R?/$)I?\`G;'TD^<1;E:Y4G/$P]8\1DO(U/Q!CN\Y5R%,
M-J_1L<U2=NEMFG9R$0CH"N1SB4DW(B<Q`.H5LV,!";[G.(%#Q$->]-3NU=0B
ME9!+SB@D#E)PCR?>;IV5/N^P@3/1C$`2'[>.9^^5A/N/]UVV#/QV1[1:7:7!
M^AF<J$92%*PV=168JRS-4IS.6;^J-TX6-,0>D9LCE7<1$=/+^H:;1U50:9:(
M]V3(ODC%*U_+GR0LUVA_4-/479R8<)[@YLP,=@PYQ$24IG3)R4Q!=1[]DYW*
M(`JT?L'S5;J*;^(LV>LW*>_T'34+]`AIMD)J$$$@@X]!^2*"5+:7C@L&?,1N
MYXM6NPSW'4.X=P@JS^X2Z+OD'@@L;BK.+4ZH?'2[Z-8%"IY$\D1%06M[@&Y5
M5E/$/UD@[*&P%#7+>N;`JPWIQ#8E0.S6@C9M(',3U0[=-W872@25X/H`"O0>
MP],/9:I\Y@'9%BC1O*`!'C-R,``$1'`^7P```1$1''UAV``#Q$1^K6Y087"G
ME_NI^NF-:L_A7/H*^JJ*55#]"C_FR?S0UV4WBVGF'FCG=W]HKG,61?RCI#E[
M9^13&*8I5.662#)F$!`#E+2<:$$2CZ!`IRB'\(:YR^*O]RC_`(Z/.J&]HD?]
M4H\H^J(D2<CN0^*^*.%<@9]S1:8RHT#'5>DIZ3?R3M%LI(N6C19:/K\,BJ<J
MLG8)UVF5LS:I`95==0"@'I$*#;J"IN=8W14J"IY9&6(`VGD`&)BTUE6U1TZZ
MEY02V@83VG8.G**7V[V3[7W2YW)1`C'[66VRVH6A0*4K+[0S;Z8^&*!?9(5M
M\;T>'A[.NQ:5M=/3):40>%`!_P`*8Y^J'/'?4X![:CZHL8_E0.-^3L+\",BY
M-R-!2=98\C\Q?;S'45+M5F+]_1*_58NKL;8#-P0BR<=99%LY.S.8H>>U1(L7
M<BA##SQ\4+A2UM^0S2K#BF&N%:MZB?.,(;6BJ%ZCMBE/"0<((YA$B[D%_N$S
MC^YW)W[$SFJ%;OYA3_?H^L(M=7_`N_=J^J8I0F_Z%/\`S:?\PNNR!["3\WU1
MSH[^T/.J+(_Y2-N1'MF7Q<HFZW7*O))U0$=R@9*H8\0+T!]`="8;_7KG7XKD
M'429;*=/G5#>T/\`RI7WG^5,.V]X+^ZUY]?\+>6?V;=:K&D_[BHO^0F)K4)/
MX+4_<JAHSY>'`6)>3_8M0P3G*G1M[QCD/*F>H6RU^2)^.D:V)G:R,:Z*'Q$7
M-Q#LA'#)VB8BS9PF4Y1`0U:-?UE5;]:JJZ)114H;;(,Y;!.?(=L0VEJ9BLT^
M*9Y/$VM9GR'NXCEB'SW?>TEEOM;9Q/#NPE+MQPR!(/G.#\PBTW3DF)/Z0K2+
MH=L3X6)R!7D5.A5,?+3D$"`Z0#I,<B;;TEJZFU)1CB(;N",'$[.=/(?RXQ0=
M06%VSODI'%2J,TJ]!](ZL,O%]J7NEYE[7>?VV0*>H]MF&KBYCHS.&&UG9R1E
MUKJ2P$_74,50PMXF_5Q!0ZD<]`NQ_:;K=2*A@#VU5I>DU-1%EP<-8GV%_H_2
M.Z/*Q7NHM%2'`9LJ]M.R7-%JEQDY,X9Y@83I'('`=P973&U\C$WT8_;&*20B
MGQ2E+)UJR1W6=>$LT"[$6[UFMLHBJ7PW()3&YAN=MJ[36KH:Y!0\@RGL4-BD
M\AAUTE8Q7,IJ:8S;4/+IB-3\S>"#K-W9?CE#&ZG',U4YRE\!\G[7823,8#;"
M4!ZS`&F%\/,*"[#9[GYDJBJ:LDE^DE+VSVJ3$MDGZ4_^5]\P?X]*^+L?5YHS
MZ(Q#;_<ZR13L88.J<Y=^==MX`13S)D7$HY9IE,@;O+69ZO7;*X2H1XR?J5Q;
MM6KY)J=^9PFV(H48\"^8!3F*:>T]3N5%6M#5(FL4&R>`J*0,1WL.KIB)O#J6
M:=*E/JI^_P"T`"3@<)'KZ(81<\PN/Z9CF_\`Z@LRM$Q$02*YX\8Q-T^GI*90
MV&T04,'T[`7?ZM7,6RL__@-'_P"17K$5E5:SMNKJ?\"8\E)\PL%'06.7YJ3*
M)%VZ2RI$F_'+')55/+**AD@;(8^:F77,4G20HF+N<0#Z=>[=MJBK@&GF9JP_
M:G#EQ),?*JMN7$+N[+[L>@0QEP_S+CKE-S-RSR\YH=W3)O''(N*S-:;QNS,^
MQVRG\PW&M==ABFKY*!BZA.4NEL&%5<=2R+=(%_C9)3I$1`YS7:[TSUJL[-KM
M-L2^RYBZWQ`)!(VDXD^B*]05"*VX*JZ^L4A;?L+*9SD<L);//#[U?Y6\<BN3
MI%^9^Y+R'2F4X$=8'JFP"D8H=8JO<,.BF`0'Q+L`FW\=45RWUB<[`P!]Y\L6
M,5E.HDBZO?J1(V[>Y59+CW'WMIS.O/.BI9(FI&T4?,U[JE6I[U.!1!.!6KD;
M%U>MU5,T:QF(ARIUN6A7'FJG`1$@%U0;V4BM*#2BD<0)%"3Q8G;.+;;1.E#G
MCE])R61(CHAN[YB?MX&YT<$Y^V46!+)Y]XO_`*URUC0&B`J2]AK39B`Y,Q^U
M$GYQ<T_7F17;5+QZI&.0`H`)QU8M`Z@-CO26G5_N=1)"Y[]BMV>'3$1JJUBX
MVY2DXU38XO\`#Y8RBK>+X[#X[>`^("`A]0E'Q*(?2`^C74"%)4CCE,[H22@4
M*D<XGS_*;]PTMWQG=^WGD>=%2T8K+)9*P(:0<[K2>.)1\"EUIC'S5.I0]/L#
MP'Z")`'9F_4V`"(^"$^*6GC35*+Y3I[CG==ED%;#TY=4-/1%V#S)MKQ[Z1-'
M-M'IZ]T3+]**&!$?'YH/P[/6;_WAX3_\1(?5X^'?]T,_0<^J8K.K?Y.?O4>>
M%W\5\)47/G::XY8`R3'%F\?Y4X-8EQ_:&2Q"&.I$V+#\%'JND.H!*D^8&6*N
MW4#Q272(<-A*&H>YU;U#JBHK&%2>;JU*'+)7D(WZ%ANJLK-.Z.XNG2#^J/3%
M4=RPXX7?B%R2S-QHR(@H2U8=O4S4'#LZ9DTYR*;*@XKEF:`(>TQL]><M7Z)@
MW#H7`-_#74UGN3=VMC%Q9,TK2">?)0ZX2%SHW*"K73/>VD_D[.R)N'RK/<=@
M9CC-E[ASF6VMHMYQ:BK!F3'\O./"I)DP,\5<RUV8E474`WPN.K"99T8"@/EL
MY(OH*EX)7XFZ>6W<FKK1";=40V9?[F2>L8=$,C1=W2Y1+I*@]YH<0^C*9ZL^
MF-]=E>OSG<,YV<QN]!DV-=?91[8I3C?PTBY5,PIP..*T"3.:L,60X`DFL>&*
MV:F53#Q>OI$-]Q'49J]Y%ALM-I2D,G.$./\`SG#D-^W+*0$;MC;7<KD[>:C]
MF"4(]'4.D$F&H_G&M_[4'#?]P5X_\0PU;_A#_`U?WP^I$!\0#.IIR<_#/GAC
MCLC_`-[3P'_?_#?]13^KEKG^U:K[GTQ6M+_SMCZ2?.(MR=<J3D)P]<-N41AO
MF&,Z7S,\EQI[._'*14-F?G#=H)UE5S''\P:;@F%EO/<K3@(',9I'3#^-7?.`
M4`H&CX=4!]E4-V+H2AIJ85&IKCA24B#P<JI9C>9F0EOBHZCJ7'UMVBG_`&SR
M@5<Q.`[)\PB0CQTP/0>+N"L4\?,71R<70\0TN$ID`B5,J:KE*):%([EGH$$2
MJ2<Y(F6>.C^(J.%SF^G5&N-;47&K<KZD\50ZLJE/:3Z$Y19:.E;IJ9%*WDA/
M".4RQ)YXK;_F0^W87A1S?D<J4&"_5N!N5ZDSDJHE8MC)Q57R*1PBKDVEE,1,
MC9J4\J^++,T@'_W9\8A0V1-MT5\.M0"[6@43Z_WRG[IVE2?S3/FPA1ZNLWX?
M6EYH?NSA)'/MZCR[H2[V2.XB\[<G.2C9"L$BY0P;E(66*<_1Y#"+=.ESD@D$
M7=10Z@*=[CR=43D2B'M&9@Y2`0\T=2&N-/)OUF6TE'[XT.)L[Y9CIRZ8T],W
M<VRO3Q&5.K!7-Y8CY8MD&+]C*L6,I%O&TC&23-M(1T@R73=,W[!ZB1RS>M'*
M)CHN&KILJ51,Y1$IR&`0'8=<MJ2I"BVL24DR(Y1G/IAWI4E20M)F%8]>79&J
M>0__`)?,\?N9RA^P\YK;H?X^G^]3]=,>%9_"N?05]544HB'Z)+^03\`:[+3[
M`^B/-'.[G[0\\31NP;PSY[9^X"6R\<5>YI=>(E>:9SO\&UQ-'8?J-ZJ;ZTL8
M&HKO+7(3\J]1G6ZDVFZ015113,5(K8#!N([:2VN;Q9*&^I8N5O14NAI)X^.4
MP2>[*6S&&+IF@N=3;BNCJUM)XO9X)[!M[(8`[K-E[B=?Y-WCCMW!\YY%RU><
M1RY`AAGK!(+X_DH63;%>5Z\T*OD;1,&C$V.+7*JDL1F1<@B=%004(<-7[2K&
MGGK:BX6)AM"'?;P[R3^@-LYQ5[Z[=$5:J6XNK6M'4?1EM`AUOY<FD]IC/^:V
M.&N4F`@EN5C=/[0X?FLGWU[9L.Y1>1`?'/X6-Q\JTAH6+O42BC\4V8/C2J$B
M@104A*HD*9ZK\0WM34%)[U;7?^KR5PIDM.\E6,QOE+U3>DD62J?#-6U*H&4U
M8*.Z6T[L3%CBT:-(]HUCV#5LQ8,6R#-BR9H)-6;)FU2*@V:-&J!$T6S9LB0"
M$3(4"D*`````:Y\))6>(J4LF9)Y8:Z0`D)`X4#`"-4\@O]PF<?W.Y._8F<UN
MV[^8T_WZ/K"/.K_@G?H*^J8I0F_Z%/\`S:?\TFNR!["?H^J.='?VAYU19,?*
M3_W8MR_XI\G?LO0=<[_%7^Y!_P`9'G5#>T/_`"I7WG^1,.Q]X+^ZTY]?\+>6
M?V;=:JFD?[@HO^0GTQ-:A_DM5]RJ&[_E8O[HV@?ONSI^UA-3_P`3/[K=^Y;\
MPB-T;_)$_3/^6'K^4G%_"W,?!]WX]9^J#2Y8WO3`6SYFKTHR<-)H@)XFT5F2
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M&BHBLF`@JSDXY<#(.VJH$6;."&34*4Q1#2TT71U-LIKS25:2A]%,4D'/V5?^
MGEBX:C?:JW:&I8,VE+,OUD8'EB927]*;^`W\[2G^7T1?3ZO-&?1!"3^8</RL
MFL913;A_'<;9+)R=OC5I)#E$RN#_`!^6HA'2Y)-2-2I*"\L2S_'G:`@8P>0"
M`K`;Q$NI.U+MZ*@FXJJ$,\.!9EQ3F,Y[)3Z91HW!%6XR$T8:+G%_Y`2)2.4M
MLY=L-6O,:]]-9(PGQ+V97IB[G(@O!YR$IS^C<#JP)RD'8?3MJQ>]Z3&;]UP^
M<C#MB$--J$9(H9?1(]$,$]Z[D3W',74:K<',W8K[<+&_\R"L8*)C>)E4N,IF
M)K!?:R$8,RJN[C%,6]?97B?$L:BX1*=RN5-P4@D`IC:O&C:*QU+J[VP_7&FI
M`5'Q2.`]TS]DXR&SIBM7]^YM(3;GT4P?>(P;3WI`S`G+"9ZY&'0N&_;G[R_#
M7CUC[`^+X[M+'K]2:NY`\I?J/EVQ7V2G+`]6F9=];+`VA4V\G-)NW@MS*H@"
M14D2$3]@I=5^[:BTK=:Y=8^;BE:L)(4`F0$A(<6'-$Q06B_4=,EAM-'P)RXD
MDJQQQ($+!;XK[[;4Y5$H+LX"<H`!@"D9X;^:`!N)3G0BP.0AC>/AJ)<K=(*0
M?#7=/$D934F0Z>*-]%+?PL%2:$H^B8?#J#*4CJK6V<XTK[&?0@XL+"UJ:"C6
ML)6$S)`TX%?;KII.$X<TH*HM_-*"HI"43^UOJE.E"GENI*U<1(3Q9@;)\LLX
ML3*"EL!02%@#B"<`3+'AY-T>B$"F*8AR%4(<!*<AR@8AR&`2G(<I@$#%.41`
M0'T@.OD8$`>U'K('"6$54G?P[=;GM]\Z+:C58P6V!>0JTWF##"Z"0D90R4I*
MF4NF/3&W,4B]+L+P00)ON,:Z:CZ>K;I_06H4WRT(#JB:UD<"MY($PKFEMWPD
MM56@VVO4M,_`69IY`=G1ES2WPVKQ`Y.WSAIR7PUR:QLX5)9\272-L1F!%CHH
M6.O]8M+54Y#H,`*QUFKSARS5*;</SH&])0U8[S;&;O:W;:\.ZM)`YSEU&1Z(
MA[96N6^N15-F121Y>CFBXGP!G&@<E\)8NS[BV43F*!EJEPEVK+PAR'.FSF&B
M:RL<\`@B"4E$/!4:.D_2DX1.4?$-<CU]$];*U=O?P=:64GED<QR'9#\I:ANK
MIT53<O#4G#DWPQ)\U--IQ/:+O3$Q^A2RYNPK"(EZND53)3SR=4*``(=8%0A3
MFV^K?Z-73X;(*]3HW):<)ZI1`ZM4!:")XEQ/KAW;MY"']@?A5]/_`-JN!/'_
M`+L:T&JQ?^$WVJ!.52L]IE$O:0K\-82<%>$GS1$O^;CX&`BOB7N'42%#H7_5
M^#L^J,FYA'S0*X<XHNDB8@>!>DCJ$76-MXF8DW]&FI\*+Z0MRP/D8@K;\Z@-
M_P`L4C75K*PBY-C;PJ[<=V7FB'QQE@<V7K-%-P_Q^EY^*R1GQW_4.T3KKMRS
M7F83*QTJM88*7.V$#JUI]%O#FD"&]CX5,YC;`&^FQ='*1FA-;6(0JE:3XB0K
M,%(S$]QBA6]+[E4&*4D+<[N&T'9TQ<%<0.,]'X<<9L+\9\>-D4JWB*C0]8^+
M23!(\W-II?%6>RNP`H"9[8[$X<O%1-N(&6VWV`-<EW:O>O%P=N#I)+CA..<A
M@D=``A\4-&W14:*5H^R,3O.WK,0BOG&%TC<IN'2`&_.I\?KDJ<-O`"+Y$5(G
M[7H$1,@;PTY_A%_`U?WP^K"X^(,S5,2'_C/UC#'/9'_O:N`GU9]AM_J_^!3^
MKIKK^U:L?^T?/%>TN/\`NV3\Y/G$6RF2\BT_$&.[SE7(4RUKU&QS4YZZVV:>
MJIHMXVOUN-<2LFY,94Z93'*U;&`A-]U#B4H;B(!KENEIGJUY%,P)O.*"0.4F
M4.]]Y%.RI]W!M"23T1!-XB8G[T7.WE%F3O0\0&W'RA*YJL%TQOB&0Y*%4D)*
M%P_`NV4!$M<>P3JL3C=A&-8B)2C5I(ITS.G!'I2`)#G,9U72JTC9K6SI*Y^,
MHM@*<\+#O'&1((F9XRZX7=&Q?J^N7>J4($R0GB(&R6T&8`PAU%>H?-GIG.1/
M*_`!T4NVRR<-"$3.&P".Q5Z.DH&P^'B4-5<+^&0S16=O^J)SAUA^DS+G3_HA
M%_.;MW?,?\_,,!B/DW(<&K]4:]/M;[`M:LI#5FY,++!LGZ*`5JPM:@W69+RK
M)XJT52,H1!P14"J"``!BS-BO^@K%7>]4'O:%%/"9\1!!E*8XB,#C$7=;5J>Y
MT_@U7A%(Q$B)Y<B03UQ!LLU<G:C8I^H6N&D("RU>8E*U98"7;*-).&FH9ZO'
M2\3(M%BE40>,7K=1)0A@\#%T\6W&ZELK8(6A8XDJV$&75"Q<;<8<+;@DZD]H
M]46/?RP?<B'E3Q0=<3LESPOLX\2XV,BH->0<BI)W3`KM465*ER"H8RSMU05P
M"">F_B(`P..YEA'7.GQ(TZ+7>?Q*G3*CJIDC8%@8@\IS`YX<&C[P*^A]U>/V
M[(SY/R]A$2(.1'_E\SO^YC*'[#SOAJ@VXE5=3$Y^(GZZ8LU;A2N3SX%?5,4H
M:/Z)+^07\`:[-:/<2=@`CG=S]HKG,66/RFR8$[6<H?RP**W)W+1C'Z>D5!+$
MTH@&$VP=?2!-M_';;;Z-<Y?%.?\`5`D1^Q3YU0X=%`FTX?I^@1^9\S1VP#\N
M>,Z/+'$E<^.Y`\6X22D)UC%,S*R^1,&$\R2M,&!4"F5?RM%5`\Q'DV$PH?&)
M%\5"!K'PYU.;1<OPVJ4?<Z@@8_FK.4N167/*,:MLOO\`2^],I'O3>/TDC?+:
M/-.*XBHVVRT2T5J\TF>DJQ;ZC.15HJEFA7:C*6@I^%>(R$1+QKQ$Q3MW;%X@
M10@@/I#8=P$0UT744]/5TZF'4S;6D@SR(.<*)IUVF>\5LE+B3U&+7_LO=S6N
M=S3B'`7V4=QS'D!C,L=0^0M1:BD@=M<&K(`97B-8D-NC6,ALT#/FO2`$0<?$
M-O2AN/*NK]..Z<NJF)3HG#Q-*W@_F\X^6'AI^[(NU$E9/[R@`+'+^ETY'EF(
M<9Y!`/\`4)G'P_\`H[DW]B9S4%;B/Q!CD?1/]81,5?\``NG9X:OJF*4%O^A2
M_D)_S"Z[);Q0F6/<](CG1WVU<ZHLFOE*4U"=L.WF,0Q2J\I<GF3,(;`<H5FA
M$,)1^D`.40'ZPUSM\4R%:E!3B/=D^=4-[1'\J5N\3_(F'8^\#L/:TY]`(_\`
MXN98_AV^S3K52TEAJ2BG_OH\YB:U`)V:JE_LJAN[Y6+^Z-H'[[LY_M835A^)
MV&JG2<O!;\PB-T=A9$D_IG_+$B_2_BU#"$K\S>'&#.=V`[AQXS]5T+!4+.U.
MK&2B2:1;'1[0@@J2%NM.DSE,I%V&$75ZTSE'H5()D52G24.09*T7>ML=<BNH
M#PN).*=BT[4JY]D:==04UR852U(F".Z9>R?+KBJ?[E/;<SKVS>04GAK+;)68
MJDL=Y+8ARU'LUT*KE&G$7`J#YDJ<GE,;)&)J)I2L:)A59.1\.M$Z2A^HM,:D
MHM24*7Z<_:2^U23WDJV2&<)*]6:HLU4IEX$M$X$`RYQY89'&/&<([W?)OD[P
M@Q*ZM,R^Q]7^8^(K;6*8\?JJUZ`M-GR%1HZQ340R5ZRQKN<90S4CH4NDBPH$
M,8!,&^O2_4S#=LK*@(":I=.L%0S4$I,@>N/BUU+ZJJGIRH^"'D$?K"+D0@_G
M3_Y7X2ZY&/MCZ,/[9Y<L9]9C$85OQ0_E!^`=?*\!.:A+=Z>2,C$RB.QW'?F$
M,6<([_E/C_COC1R#SKR#QX+&,$J=%DZYAE*;EH9G,LEG-X*1_+SD6R:R2)EO
MU<P4\X_4D14@@8Y;U8-$/WIMNLJ:AEFC5GB..7-EUGHBL7/4":):F6&%K?3D
M=D^43G+HZ8@R!S%YDW7N,X_[C6>\.Y'R]D*H9?I^275.<8]NL76"UZGOTE(C
M'M70/"/25^!A8H/)CPV5%-8H+J^8H90QG9^&V2CT^Y8;?4--)4VI/%,=XE)$
MU<LS"Y54W1ZZIN=2VI9XLMV.SJR$6"W#;OI<4^9^2\?87K.+>5F,LJY"2>`V
MA,G8&LL558B0CHAW,/F<ED"/-(5I!$$&*A$%U3HD64Z2@`&.`:0EUTA<;0VN
MH+U.Y2(.:%I)/^$XXPTJ*^4M6I*.!2'E;#(]<CVRE#T8ZJT^+&)J.-$$)0YC
M\R\0\&\6QV7<SQN3I:L2MMCJ4Q8XGQK9LIV92;E&$I)MA4K]6:N7C6-!K$+>
M8Z5Z$"'Z""8#'*`R%KME5=W_`'6E*/$E/[0A(ESQJ5=:U1("W@2E64OE(';R
M1!,^8&[D<=W/V&"\;<=N)7)IA5\,62TVUWE#)&&[97IV<>6:'9PPUROUIE'R
MCEC!E(T*X<KNUB*K+IH@1$H$,8SKT#84:;6[4W"JI_$<2`$H5@)9G&6<+C5-
M<N[(;8I6%!*">]ACEN/)$:`,#9VW_P!R.8P_[K;W_L#3._%K9M?:E](12OPV
MN_VE=D26NROWE.27;;I#GC?G?B?R$R_QJ6GWUBJ+JHX[MJ.1,324TL56>:0K
M&;B&D19*A*.NIV+`[EHLU='4.B<P*F3TLM9:5ME]?3<;?54Z+A+OS4.%6Z7*
M-\773MYK[4V:2J:6MB<P1*8ZSUSC;??Y[KT?W(\$8OXV\8^,G*]M58C(D;E>
M_73(^%+=555)&%K\_!PM2A(!FUF%W?EJ6)5PY>+'33**29$BGZC&+J:$TY^`
M5CEQNE53%104A*5XF9!GD!E&UJ:ZN7&G33T;3F"IDGAEE+83E#KO:I[[N*8_
MC=QHXR<E>/\`RFQAFFBP./L#-9:#X^W^S8VM:,0E&4NHV@LVQC_BZT5^S*V&
M13>H%2:+%54*J9$0$*OJG1S_`.)/W"WO4SM&M2G,5CB3,DE.>,O4(FK'>FTT
M35+5MN)>0.&>!G+;G/L.,2(>7_&>D<Q.,V:N,N0D4CUK+U&F*L=X9,JJD'-*
M)%=UFRLP,4PD?5NQM6KY$0\>M``]`ZHEJN#EJN#5RIRKB;6)R.$MO7E%BKZ1
M%=2.4KGYR<.0[#\L0X_EG.U%D''7+_D7R-Y'T=]"2?$>U6KC]CAE-Q;ALVE<
MNJBXCKI=(/XYL1-]%P-14339.TA,0QICK(;J3\&S\1=6,55K9M]O7--4$K7P
MYA/Z(Y]L4725A4Q6NU-0G]D9)GOWX[M_+$RKE%R8QCQ!PI:\_9A^UWV`IJD0
ME,_8:GS=[L@GG)5K#,`8UJO-G<H\*+YZ0%#$)TI$W.80*`B"CHJ)ZXU2:.F*
M.-0PXS(=<7ZKJFJ1DO/B;0E.7EV[-L5Q_P`P/SCJ/<RY+XDO''+$6>R4#$F)
MW%$5L%YQ99JT^L\S+6A[8W3F.@!9O'C&,CD5R(E.Y,1593J$$RE`!'H'X?6E
MS3=O>8N#S`<<<X@`H&0YX5NJGU7:J0JD;6$(1*9ER[B8;3[?M_M7$/FOQFY,
MW##&7;-5,+Y4A+G9(.O4>?+.R$*@@]CY`L0#Z.09JR#9M(&623543(J9/H$Y
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MA<UCB5M')/(=D6.QWA@TC-(MM3;P1P\(EPS'3/'FB3((;"(?X-4`$$&+3NA&
M?,WG;@_@A4Z?<\X1^5Y*+O,^]K<"WQ-BBY98E?UE'QPRBXR<=3X]^M$,Q;!L
M1=QY:1U!Z0'?4E;+15WAU3-(6P4B9XU!(QP&)Y=T:E76,420I^>)PEY"*T+O
M!6>!YE<^,O\`(SBOQFY%U3&V0VU7=R@VS"MPKTE:+W'PZ,;:KF2`:1;T8E&P
MJ-45#$64^(57*HLH4IE>D.CM'$V:QMT%TJF%5")R`6#('9.$_J)A=;<UU%$P
MI+)YNO`[=T:5[?\`F#E]V^.56,^4&,\&9CE'M,>.(^V4];'&0&,;D''\Z0C2
MV4J473KJ@(I2;,I56ZPD/\*^;H+@413`-;FH&++J"VKH*A]D!8[IXA-"MBAZ
M=\:]H-SM-8FI:;5GWAL(V@X[?EB<KFCYB3B9<.,.2FE6P)S9=95NV)K;7HG%
MLEQCR`Q48VRS5A]$-XV7N0,UJL2+8OWVZKQNLMU($$Q$Q,($TD:/0]S8N+?B
M5%*:9+P/B!P`\*2,9<LMT,JHOU,JB7X3;OO"D&2<,)B6_P`MT5S"6!,[$33*
M.$,Q^R4I1Z<6WS;V0V';>`WV\-=$BZVX=TOM;I\0,*15OK5.%0;5(F>SUQ,G
M[!'=<Q!P)X?3?&/E#A'E=4;#'Y:ME]KMJJ_'?)-YKUAB+FWARF9+)0L(,K#R
MD0\C3E.51`Z*R2A3%4`P&+I-Z\TZ[>+Q^)VEVG53J;2DIXPD@@F9F3M\A##T
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M$4%QQOM\<HVL=BK+^+8L)NSB9Q7F;)%Z\`%7*"S@`3*8Q2&'8HI2AT)=*:YL
MK>=IDTR'4DJ"QB$J!F1O.<,:HU!2+I7.%M?C+0>[A(3$I9^:*Y5/#.8DTR)C
MB/*8B4A2B(8XNFVY2@`^F$W](:Z*3<[<D!*JAJ8.?$,AZX4*Z"L4HJ#:L2=V
M_GB7?V`N[CC'MZ\9[SQGY2X0Y110.,LSV2J;<Z+@FVW*'7C[/"U]C(PLRS:H
M-9IC(,Y&%.J10J"R*B2X!U%$H@*AUWIU5\N2;I:WZ<DMA*DJ<`((.S9VPP-+
MW/\`#:9=-5-N!/',$2RD!M(W0I/NZ=_V@<CN'F6.,/#[CMRFF[1G*#7H%LON
M1\'6BEUZJT*4,D-G5AF)BR4Q,6"98)F9(%.@@BW(L=8QA.0A#1VD]%^XWAJO
MNU33ML,JX@$+XB2,ACE&W?;[[Q1.4E&TXHN"1)(RW2!\A.-$]A3O'4#@CQ;>
M\2^47'CD]#-:[?[9>*/D7'6$;M>F,M&W1PA(RT/9H!I'MYN+?PLBDH9)=NDY
M1<-U"E$J9TQ\S>UYIE5ZN?XS;*BF5Q-@+05@9#S[_ECPTO=U4%'[C6-$`'`X
M;><B)Q^-,@U_+..J)E&IDF$ZQD2I5^Z5].P0S^NSR</9(QM+1Q)F`E4F\E"R
MA&KHH+M7!"+(*;D.`&`0TG7V%TSRJ=R7&@R,B",-Q$P8OK+B7FPZF80H3$Q(
MRY1'M]>4L9[8](1=SSX'8%[B/'VR<?L\P7Q$>^*K)4F[QJ#;[88ONB:!TXNY
M4]^X3.+=ZV.8"N6YA^'?M1.@L`D-N$K9+U66"N%=0D@`]])."T[1Y8C9&A<[
M;372F--4`<,L#M!.WU[XK3S<`L^=NGNX\3N/F<H81<%Y5X*D\<7V,;N"5#+-
M*4RQ6T8VUU)VN4H*"?8$GK(P_$Q[L#)*E_$,;HS^H:&_Z5J*RF(\3W=86G\Y
M)X3@>3EVPH/PBIM5\;IUI/!XJ9'81Q#&<6Q)/TIO\K\.N73[8^CZH=T?1K,$
M<#M_&VV^O;_GT'+'*",!OA.OV_A_,V#\;RNO;^+Z?:VV]&OH<?")3X-F[HCS
M/@\1GP\?1.,WL_D_>UC'EC/V?S>R`>CQWZ?1X[[>CZ_JU@Y=[*,C@GA*<'L?
M1T[?<T1]0>Q^3][1!`'1O[/3O].VV^WW-!SQ]J79!LY([:((-$$&B"#1!!H@
MCH'E_1T?<Z=8[O!L\/L]4!]K'VNV.`\K<=O+WW'?;IWZO#??Z_1OK)GA/H^2
M/D<./#+EC@_D[#YGE=.WM=?1MM]>_AMOK*>*?=G/D@7P<!\27A[9Y=,\(P_T
M'8-OA-OH_0[?<U]_:SQXI],>?V&S@[(/Z#_JG^AT?:_.[8S]A\SLCG^@_P"J
M_P"AT?:_.[8/L/F=D`?!=0=/PO5OX;>5U;_1MMX[Z^>_RP?83_-GT1G_`#?T
M='WM?.$>ISQSCD.G^+T_<V_YM$$=M$$&B"#1!!H@@T01U]C\G[WIT;>6,82Q
ME*,1_AMB^;Y&V_L]?E[;_3T]7T[:RW.1\*<MLO3*/E?AX<<I;)QC_H/^J?Z'
M7U]IMXNV/G[#YG9&5/X?Q\KR?HW\OH^O;?IU\][EC(\+9P]D9/8_)^]H[W+!
M]EMX>R#V/R?O:.]RP?9?-[(/8_)^]HQY8S]GLX>R.?#?PVW^YOHQC(X9X2G'
M`]/T]._U[:Q'U!['Y/WM$$'L?D_>T<T$)RSB7B*:T8=_M)?V<_MH%R1'`']=
MQL:%M']8`.HWR/ZG_MT(2PV_XWX/I"%_IGF^3M[71J1HOQ;PG?P[WCP>'[3P
M^/AX<?;X<)9^UAG&I4^X^*GWOPO&GW>/AXISPX9XYRRVPH[V=_#;?[F^H["?
(+&W'.B"/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
